BioCentury | Jun 7, 2017
Distillery Therapeutics

Cardiovascular; hematology

...samples from healthy volunteers. In a mouse model of diabetes-induced thrombocytosis, the S100A9-targeting small molecule paquinimod...
...compared with vehicle or normal S100A9 expression, respectively. In a mouse model of diabetes-induced atherosclerosis, paquinimod...
...S100A9 inhibitors in the models. Active Biotech AB has the immunomodulator paquinimod ( 57-57 ; ABR-215757...
BioCentury | Jun 5, 2014
Distillery Therapeutics

Indication: Cancer

...in Phase II trials to treat gastric, liver, ovarian and renal cancers. Active Biotech's paquinimod (ABR-215757...
BioCentury | Jun 5, 2014
Distillery Therapeutics

Indication: Cardiovascular disease

...in Phase II trials to treat gastric, liver, ovarian and renal cancers. Active Biotech's paquinimod (ABR-215757...
BioCentury | May 29, 2014
Targets & Mechanisms

S100A9-clot not, bleed not

...the compound in Phase II testing to treat Huntington's disease (HD). Active Biotech's paquinimod ( ABR-215757...
BioCentury | May 5, 2014
Clinical News

Paquinimod regulatory update

...Biotech disclosed in its 1Q14 earnings that in January FDA granted Orphan Drug designation to paquinimod...
...Phase II testing. Active Biotech AB (SSE:ACTI), Lund, Sweden Product: Paquinimod ( 57-57 ) ( ABR-215757...
BioCentury | Feb 27, 2012
Clinical News

Paquinimod: Phase I started

...its 4Q11 earnings that in November it began an open-label Phase I trial to evaluate paquinimod...
...treat systemic sclerosis. Active Biotech AB (SSE:ACTI), Lund, Sweden Product: Paquinimod ( 57-57 ) ( ABR-215757...
BioCentury | Aug 22, 2011
Clinical News

Paquinimod regulatory update

...In February, EMA granted Orphan Drug designation for Active Biotech's paquinimod to treat systemic sclerosis. The...
...indication this year. Active Biotech AB (SSE:ACTI), Lund, Sweden Product: Paquinimod ( 57-57 ) ( ABR-215757...
BioCentury | Jun 13, 2011
Clinical News

Paquinimod: Phase II data

...in 13 patients with mild active SLE showed that once-daily 1.5 and 3 mg oral paquinimod...
...Against Rheumatism meeting in London. The company plans to start a Phase IIa trial of paquinimod...
...Europe, this year. Active Biotech AB (SSE:ACTI), Lund, Sweden Product: Paquinimod ( 57-57 ) ( ABR-215757...
BioCentury | Mar 29, 2011
Top Story

Cephalon to acquire ChemGenex

Cephalon Inc. (NASDAQ:CEPH) will acquire the 72.4% of cancer company ChemGenex Pharmaceuticals Ltd. (ASX:CXS) it does not already own for about A$159 million ($163 million) in cash. The deal, which comprises A$0.70 per share and...
BioCentury | Nov 22, 2010
Clinical News

Paquinimod regulatory update

...The COMP issued a positive opinion to grant Orphan Drug designation for Active Biotech's paquinimod to...
...of the European Medicines Agency (EMA). Active Biotech AB (SSE:ACTI), Lund, Sweden Product: Paquinimod ( 57-57...
Items per page:
1 - 10 of 20